Biggest News Aggregation in the World
📰 Daniel Curran News

Page 2 - Daniel Curran News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Daniel Curran. Real-time updates on events, politics, business and more.

Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

05.01.2023 - Takeda (TSE:4502/NYSE:TAK) today announced that the totality of evidence from a pre-planned interim analysis of a pivotal Phase 3 study supports the efficacy and safety of TAK-755 as enzyme replacement therapy for congenital thrombotic ... Seite 1
Daniel Curran Confidence Interval Hematology Therapeutic Area Unit New England Journal Takeda Yakuhin Kogyo

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies

− If Approved, Maribavir Would be the First and Only Inhibitor of CMV-specific UL97 Protein Kinase in the EU for Treatment of Adults with Post-transplant CMV Refractory to Prior... | September 16, 2022
United States Daniel Curran European Commission Drug Administration Exchange Commission European Union

Takeda Pharmaceutical Company Limited: Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies

If Approved, Maribavir Would be the First and Only Inhibitor of CMV-specific UL97 Protein Kinase in the EU for Treatment of Adults with Post-transplant CMV Refractory (With or Without Resistance) to
United States Daniel Curran Abhi Basu Jun Saito Erin Marie Beals European Commission

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science